[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes[J]. Pancreatology, 2015, 15(1): 8-18.
[3] Siegel R L, Miller K D, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[4] Kamisawa T, Wood L D, Itoi T, et al. Pancreatic cancer[J]. Lancet, 2016, 388(10039): 73-85.
[5] Muniraj T, Jamidar P A, Aslanian H R. Pancreatic cancer: a comprehensive review and update[J]. Dis Mon, 2013, 59(11): 368-402.
[6] Chames P, Kerfelec B, Baty D. Therapeutic antibodies for the treatment of pancreatic cancer[J]. ScientificWorldJournal, 2010, 10: 1107-1120.
[7] Le N, Sund M, Vinci A, et al. Prognostic and predictive markers in pancreatic adenocarcinoma[J]. Dig Liver Dis, 2016, 48(3): 223-230.
[8] Coperchini F, Croce L, Marino M, et al. Role of chemokine receptors in thyroid cancer and immunotherapy[J]. Endocr Relat Cancer, 2019, 26(8): R465-R478.
[9] Fang H, Declerck Y A. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials[J]. Cancer Res, 2013, 73(16): 4965-4977.
[10] Roma-Rodrigues C, Mendes R, Baptista P V, et al. Targeting Tumor Microenvironment for Cancer Therapy[J]. Int J Mol Sci, 2019, 20(4).
[11] Wu T, Dai Y. Tumor microenvironment and therapeutic response[J]. Cancer Lett, 2017, 387: 61-68.
[12] Mertins P, Mani D R, Ruggles K V, et al. Proteogenomics connects somatic mutations to signalling in breast cancer[J]. Nature, 2016, 534(7605): 55-62.
[13] Shah N, Wang P, Wongvipat J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer[J]. Elife, 2017, 6.
[14] Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nat Med, 2015, 21(11): 1350-1356.
[15] Klemm F, Joyce J A. Microenvironmental regulation of therapeutic response in cancer[J]. Trends Cell Biol, 2015, 25(4): 198-213.
[16] Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612.
[17] Ritchie M E, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
[18] Szklarczyk D, Gable A L, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-D613.
[19] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
[20] Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma[J]. Cancer Sci, 2019, 110(5): 1564-1572.
[21] Yan H, Qu J, Cao W, et al. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis[J]. Cancer Immunol Immunother, 2019, 68(12): 1971-1978.
[22] Liao H, Chen W, Dai Y, et al. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes[J]. Front Oncol, 2019, 9: 883.
[23] Merlano M C, Abbona A, Denaro N, et al. Knowing the tumour microenvironment to optimise immunotherapy[J]. Acta Otorhinolaryngol Ital, 2019, 39(1): 2-8.
[24] Xiong Y, Wang K, Zhou H, et al. Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study[J]. Cancer Med, 2018, 7(9): 4496-4508.
[25] Heeren A M, Koster B D, Samuels S, et al. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer[J]. Cancer Immunol Res, 2015, 3(1): 48-58.
[26] Punt S, Corver W E, Van Der Zeeuw S A, et al. Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival[J]. Oncotarget, 2015, 6(36): 38681-38694.
[27] Eo W K, Kwon S, Koh S B, et al. The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer[J]. J Cancer, 2016, 7(5): 538-545.
[28] Protti M P, De Monte L, Di Lullo G. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies[J]. Tissue Antigens, 2014, 83(4): 237-246.
[29] Adams O J, Stanczak M A, Von Gunten S, et al. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer[J]. Glycobiology, 2018, 28(9): 640-647.
[30] Mcdonald P C, Chafe S C, Brown W S, et al. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia[J]. Gastroenterology, 2019, 157(3): 823-837.
[31] Michaud D, Mirlekar B, Bischoff S, et al. Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3[J]. Cytokine, 2020, 125: 154817.
[32] Supuran C T, Winum J Y. Carbonic anhydrase IX inhibitors in cancer therapy: an update[J]. Future Med Chem, 2015, 7(11): 1407-1414.
[33] Vitoratou D I, Tolia M, Liakos P, et al. Clinical value of significance of Hypoxia Inducible Factor-1alpha, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy[J]. J BUON, 2019, 24(2): 456-463.
[34] Giatromanolaki A, Harris A L, Banham A H, et al. Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration[J]. Br J Cancer, 2020.
[35] Iikuni S, Ono M, Watanabe H, et al. Cancer radiotheranostics targeting carbonic anhydrase-IX with (111)In- and (90)Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy[J]. Theranostics, 2018, 8(11): 2992-3006.
[36] Lou W, Ding B, Zhong G, et al. Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer[J]. Aging (Albany NY), 2019, 11(23): 11416-11439.
[37] Sambuudash O, Kim H S, Cho M Y. Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer[J]. Yonsei Med J, 2017, 58(4): 749-755.
[38] Ren F, Wang D B, Li T. [Epigenetic inactivation of SPOCK2 in the malignant transformation of ovarian endometriosis][J]. Zhonghua Fu Chan Ke Za Zhi, 2011, 46(11): 822-825.
[39] Ren F, Wang D, Wang Y, et al. SPOCK2 Affects the Biological Behavior of Endometrial Cancer Cells by Regulation of MT1-MMP and MMP2[J]. Reprod Sci, 2019: 1933719119834341.
[40] King L A, Lameris R, De Gruijl T D, et al. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond[J]. Front Immunol, 2018, 9: 1519.
[41] Melo A M, Conroy M J, Foley E K, et al. CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies[J]. Cancer Immunol Immunother, 2020.
[42] Seki T, Liu J, Brutkiewicz R R, et al. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer[J]. Anticancer Res, 2019, 39(2): 549-555.
[43] Toyoda T, Kamata T, Tanaka K, et al. Phase II study of alpha-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer[J]. J Immunother Cancer, 2020, 8(1).
[44] Kanamori T, Numata T, Kuwabara S, et al. Photo effect on the CD1d-binding ability of azobenzene-attached analogues of alpha-GalCer[J]. Bioorg Med Chem Lett, 2020, 30(5): 126960.